ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the U.S. Food and Drug Administration (FDA) has authorized the company to proceed with the Investigational New Drug (IND) application for ONL1204 Ophthalmic Solution, a first-in-class small molecule Fas inhibitor designed as a neuroprotectant for key retinal cells.